Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lixte Biotechnology Holdings (LIXT) Liabilities and Shareholders Equity (2016)

Lixte Biotechnology Holdings' Liabilities and Shareholders Equity history spans 7 years, with the latest figure at $933561.0 for Q3 2016.

  • For Q3 2016, Liabilities and Shareholders Equity fell 9.1% year-over-year to $933561.0; the TTM value through Dec 2016 reached $3.5 million, down 26.8%, while the annual FY2015 figure was $597975.0, N/A changed from the prior year.
  • Liabilities and Shareholders Equity reached $933561.0 in Q3 2016 per LIXT's latest filing, down from $1.4 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.3 million in Q2 2012 to a low of $187867.0 in Q1 2014.
  • Average Liabilities and Shareholders Equity over 5 years is $1.2 million, with a median of $1.2 million recorded in 2013.
  • Peak YoY movement for Liabilities and Shareholders Equity: crashed 87.32% in 2014, then skyrocketed 795.32% in 2015.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.8 million in 2012, then tumbled by 68.17% to $558040.0 in 2013, then skyrocketed by 78.51% to $996170.0 in 2014, then plummeted by 39.97% to $597975.0 in 2015, then soared by 56.12% to $933561.0 in 2016.
  • Per Business Quant, the three most recent readings for LIXT's Liabilities and Shareholders Equity are $933561.0 (Q3 2016), $1.4 million (Q2 2016), and $1.2 million (Q1 2016).